Icatibant Medical Valley (Icatibant)

Icatibant is a selective competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin from causing vasodilation and increased vascular permeability, which are the primary mechanisms behind the swelling seen in hereditary angioedema.

The dose of icatibant is determined by the prescribing clinician based on the patient’s condition and clinical guidelines. Typically, a single subcutaneous injection is given at the onset of an HAE attack, with additional doses administered only if medically indicated.

Safety data for icatibant in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

The primary alternative for HAE is C1‑esterase inhibitor replacement therapy, which restores deficient protein function. Icatibant, by contrast, blocks the bradykinin B2 receptor directly, offering a rapid, receptor‑targeted approach. Choice of therapy depends on patient preference, attack severity, and clinical response.

Icatibant should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. If refrigeration is temporarily unavailable, the product may be kept at controlled room temperature for a limited period as specified in the product label.

Icatibant is administered as a subcutaneous injection, usually into the abdomen or thigh. The injection site should be cleaned with an alcohol swab, and the medication delivered using the pre‑filled syringe provided, following aseptic technique and the prescriber’s instructions.

The most serious adverse reactions include anaphylaxis, severe angioedema affecting the airway, and hypotension. Patients should be monitored closely after injection, and any signs of respiratory distress, swelling of the face or throat, or sudden drop in blood pressure require immediate medical attention.

Icatibant is contraindicated in individuals with a known hypersensitivity to icatibant or any of its excipients. Caution is also advised for patients who have experienced severe allergic reactions to other bradykinin‑targeting agents.